Massimiliano Paganelli, MD, PhD​

Co-Founder and Interim Chief Executive Officer


Max is a Pediatric Transplant Hepatologist,  the Head, Hepatology and Cell Therapy Lab, Sainte-Justine UHC,  and an Assistant Professor, Pediatrics, Université de Montréal.

Max earned his medical degree at the Sapienza University of Rome, and trained in pediatrics in Rome and in pediatric hepatology and transplantology in Naples and in Brussels. Max also has a Ph.D. in hepatology and cell therapy from the Catholic University of Louvain. Expert in cell therapy of liver diseases, he is a Stem Cell Network investigator and a CIHR/FRQS-funded scientist. Driven by the needs of his young patients, Max is seeking better ways to treat liver disease using novel stem cell therapies. With his team at Sainte-Justine UHC, he developed the Encapsulated Liver Tissue, on which Morphocell Technologies’ ReLiver™ technology is based. 


Claudia Raggi, MD

Co-Founder and Chief Technology Officer


Claudia spearheads the stem cell biology, differentiation and cell manufacturing team at Morphocell. Educated in medicine at the University of Rome La Sapienza and at the Catholic University of Louvain, Claudia has been a full-time basic and translational scientist since 2009, She is an expert in development and stem cell differentiation. Claudia and Max met as medical students in Rome and have been partners in science as in life (they were married in 2006) sharing their passion for science and a mission to cure untreatable diseases. 

Jennifer Moody, PhD

Chief Operating Officer

Jennifer brings to Morphocell 13 years of business and operations management in regenerative medicine, spanning the commercial development of reagents through to cell based therapeutics. Jennifer obtained a BSc in genetics from York University (Toronto), a PhD in Genetics from UBC (Vancouver), and pursued postdoctoral studies in Lund, Sweden. At STEMCELL Technologies in Vancouver she led commercial development of the TeSR product line. At the Centre for the Commercialization of Regenerative Medicine (CCRM) in Toronto she functioned in operations, alliance management and business development roles. At BlueRock Therapeutics she was instrumental in establishing the company’s pluripotent stem cell platform to enable its clinical programs. Jennifer is a member of ISSCR and ISCT, serves on the ISCT Business Model and Investment subcommittee and is a member of the Rotman Business School Healthcare and Life Sciences Leadership Network.